BioLineRx, Ltd.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Tel Aviv Israel (2003)

Organization Overview

First Clinical Trial
2006
NCT00374881
First Marketed Drug
2023
Motixafortide (Aphexda)
First NDA Approval
2023
Motixafortide (Aphexda)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BioLine Rx | BioLineRx, Ltd. | BIOLINERX, LTD. | Biomix

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 2)

Adenocarcinoma (Phase 2)

Anemia (Phase 2)

Anemia, Aplastic (Phase 2)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Disease (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hodgkin Disease (Phase 2)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Mood Disorders (Phase 2)

Multiple Myeloma (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Pancreatic Neoplasms (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Preleukemia (Phase 2)

Psychotic Disorders (Phase 2)

Schizophrenia (Phase 3)

Syndrome (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 24
  • # of Trial APIs: 28